MET and lung carcinoma: Additionally, in vitro preclinical models may provide additional information predicting therapeutic response and suggest the appropriate approach for MET and HER2 treatment in MET and HER2-overexpressed lung cancer without RTK/RAS/RAF oncogene alterations.